相关实验视频

Updated: Jun 29, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

化疗启动的富含囊蛋白61降低了急性B型淋巴细胞白血病的化学敏感性

Pengchong Shi¹, Zhen Lin¹, Yanfang Song²

¹Department of Clinical Laboratory, Fujian Medical University Union Hospital, 29 Xinquan Road, Fuzhou, 350001, Fujian, China.

Journal of cancer research and clinical oncology

|March 26, 2024

概括

富含氨酸的蛋白质61 (Cyr61) 通过增加存活率来降低B细胞急性淋巴细胞白血病 (B-ALL) 的化学抵抗. 准Cyr61或ATM通路可能会改善B-ALL患者的治疗敏感性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
细胞生物学细胞生物学

背景情况:

化学抵抗在治疗急性淋巴细胞白血病 (ALL) 中是一个重大障碍.
富含氨酸的蛋白质61 (Cyr61) 与瘤细胞耐药性有关,在ALL患者的骨髓中升高,促进ALL细胞的存活.
Cyr61在B细胞急性淋巴细胞白血病 (B-ALL) 化学敏感性及其骨髓调节中的特定作用尚不清楚.

研究的目的:

调查Cyr61对B-ALL细胞对鲁素 (DNR) 化学敏感性的影响.
阐明骨髓微环境中控制Cyr61生产的调节机制.

主要方法:

使用了Nalm-6和Reh人类B-ALL细胞系.
通过定量实时PCR (qRT-PCR),西部涂抹和ELISA评估Cyr61水平.
通过细胞活力测定和流细胞计,评估B-ALL细胞对DNR的化学敏感性.
通过使用qRT-PCR和西部斑点检查Cyr61生产规则.

主要成果:

Cyr61敲击增强了B-ALL细胞对DNR的化学敏感性,而过度表达则降低了它.
Cyr61通过上调 B 细胞淋巴瘤-2 的调节减弱了 DNR 诱导的亡.
达努鲁比通过ATM依赖的NF-κB通路诱导了DNA损伤反应和Cyr61分泌.

结论:

达努鲁比治疗刺激了B-ALL细胞中Cyr61的产生,导致化学敏感性降低.
针对Cyr61或相关的ATM信号通路提供了改善B-ALL化学敏感性的潜在策略.

关键词:

细胞灭亡 (apoptosis) 是一种死亡的过程.化学敏感性化学敏感性在Cyr61中使用.造成的DNA损伤是DNA损伤.

更多相关视频

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...